Mylan Executive Chairman Robert Coury is telling Teva Pharmaceutical Industries to “stop playing games with our company” in a strongly worded letter released Monday.
Teva said back in April it wanted to make a $40 billion bid to acquire the generic pharmaceutical company that is run out of Washington County. The bid was rejected by Mylan’s board — and Coury in a strongly worded responses — but Teva has kept interest even as Mylan pursues its own unsolicited bid for another generic pharmaceutical company, Perrigo plc.
Coury wrote that without “an actual offer” or the timing, Teva should provide “unequivocal clarification” about what it wants to do with Mylan. The letter was sent to Teva’s CEO and also filed with the SEC.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Caroline Ellison Seeks Leniency After FTX Fraud Cooperation
Sep 11, 2024 by
CPI
UK Competition Watchdog to Investigate Carlsberg’s £3.3bn Takeover of Britvic
Sep 11, 2024 by
CPI
News Corp Faced Millions in Losses by Moving Away from Google Ads, Ex-Executive Testifies
Sep 10, 2024 by
CPI
EU Faces Critical Innovation Gap, Draghi Report Urges Antitrust Reforms
Sep 10, 2024 by
CPI
Womble Bond Dickinson and Lewis Roca to Merge, Forming 1,300-Lawyer Firm
Sep 10, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI